Skip to main content
OpenTrials

Clinical trial condition

Renal Tubular Transport, Inborn Errors

Explore clinical trials studying Renal Tubular Transport, Inborn Errors. Study availability and eligibility vary by location and protocol.

92 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Renal Tubular Transport, Inborn Errors trial results

Completed

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

NCT04842032

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • Peking Union Medical College Hospital Beijing, China
  • Guangzhou Women and Children Medical Center Guangzhou, China
  • Shanghai 6th Hospital Shanghai, China
  • Shanghai Xinhua Hopsital Shanghai, China
View Trial Details
Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

NCT01571596

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Clinical Research Center, Indiana University School of Medicine Indianapolis, Indiana, United States
  • Duke Clinical Research Unit Durham, North Carolina, United States
View Trial Details
Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • University of California-San Francisco Medical Center San Francisco, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Indiana University Department of Medicine Indianapolis, Indiana, United States
View all 25 locations
View Trial Details
Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

NCT02537431

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • UCSF Medical Center at Mission San Francisco, California, United States
  • Yale University School of Medicine - Yale New-Haven Hospital/Yale Center for Clinical Investigation New Haven, Connecticut, United States
  • Indiana University Department of Medicine University Hospital Indianapolis, Indiana, United States
  • Duke University Medical Center Durham, North Carolina, United States
View all 14 locations
View Trial Details
Completed

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

NCT01340482

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • University of California, San Francisco Medical Center San Francisco, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Clinical Research Center, Indiana University School of Medicine Indianapolis, Indiana, United States
  • Duke Clinical Research Unit Durham, North Carolina, United States
View Trial Details
Completed

A Study of KRN23 in X-linked Hypophosphatemia

NCT00830674

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • Yale University School of Medicine New Haven, Connecticut, United States
  • General Clinical Research Center, Indiana University School of Medicine Indianapolis, Indiana, United States
  • Duke Clinical Research Unit Durham, North Carolina, United States
  • University of Texas Health Science Center at Houston Houston, Texas, United States
View Trial Details
Completed

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

NCT02312687

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • University California San Francisco Hospital San Francisco, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Indiana University Hospital Indianapolis, Indiana, United States
  • Duke University Durham, North Carolina, United States
View Trial Details
Completed

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

NCT02163577

Conditions
Avitaminosis, Bone Diseases, Bone Diseases, Metabolic, +26 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Indiana University Hospital Indianapolis, Indiana, United States
  • Shriners Hospital for Children St Louis, Missouri, United States
View Trial Details
Completed

Registry of Thiola EC Therapy

NCT05048563

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystinuria, Female Urogenital Diseases, +8 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • NYU Langone Health New York, United States
  • Duke University Durham, North Carolina, United States
  • University of Texas Southwestern Dallas, Texas, United States
View Trial Details

Related conditions